Chronicle Journal: Finance

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Abbott Laboratories (NY: ABT)
89.59 USD  -0.81 (-0.90%)
Official Closing Price  /  Updated: 5:32 PM EST, Jan 27, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 4,482,196
Open 89.11
Bid (Size) 89.12 (1)
Ask (Size) 91.77 (1)
Prev. Close 90.40
Today's Range 88.89 - 90.00
52wk Range 68.80 - 92.45
Shares Outstanding 1,753,187,766
Dividend Yield 1.25%
Performance
YTD
+3.04%
+3.04%
1 Month
+2.51%
+2.51%
3 Month
+8.38%
+8.38%
6 Month
+1.17%
+1.17%
1 Year
+29.75%
+29.75%
Top News
More News
Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease
- Abbott's Infinity™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions Read More
from PR Newswire
New Quality of Life and Functional Improvement Data From Abbott's BOLD and TRIUMPH Studies Reinforce Benefit of Proclaim™ XR Neurostimulation System In People Living with Chronic Pain
- BOLD study found that BurstDR™ stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62% Read More
from PR Newswire
More News
Read More
Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020
from PR Newswire
Better Buy: DexCom vs. Abbott Laboratories
category DXCM , Market News , ABT
from Motley Fool
Abbot's Brain Stimulation System Approved to Treat Parkinson's
category Market News , ABT
from Motley Fool
Abbott's Brain Stimulation System Approved to Treat Parkinson's
category Market News , ABT
from Motley Fool
Abbott's Proclaim XR Neurostimulation Implant Device Said to Reduce Pain
category Market News , ABT
from Motley Fool
UPDATE 3-Abbott hits all-time high on quarterly revenue beat
category companyNews
from Reuters: Company News
Incoming Abbott CEO says not looking to do any deals
category companyNews
from Reuters: Company News
Abbott Laboratories (ABT) Q4 2019 Earnings Call Transcript
category Market News , ABT
from Motley Fool
Abbott Laboratories Beats Revenue Expectations With Balanced Growth
category ABT , Market News
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]